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Abstract
Background: The chemokine CXCL13 is known to dictate homing and motility of B cells in lymphoid tissue and
has been implicated in the formation of ectopic lymphoid tissue in chronic inflammation. Whether it influences B
cell trafficking during acute infection, is largely unclear. In previous studies, we showed that (I) CXCL13 levels are
markedly increased in the B cell-rich cerebrospinal fluid (CSF) of patients with acute Lyme neuroborreliosis
(LNB), and (II) CXCL13 is released by monocytes upon recognition of borrelial outer surface proteins by Toll-
like receptor 2. Here, we assessed the role of CXCL13 - in comparison to other chemokines - in the recruitment
of B cells to the CSF of patients with acute LNB.
Methods: Measurement of chemokines was done by ELISA. B cells were isolated from whole blood using
magnetic cell separation (MACS). For migration experiments, a modified Boyden chamber assay was used and the
migrated B cells were further analysed by FACS. The migration was inhibited either by preincubation of the CSF
samples with neutralizing antibodies, heating to 60°C, removal of proteins >3 kDa, or by pre-treatment of the B
cells with pertussis toxin. The principal statistical tests used were one-way analysis of variance and Bonferroni
test (chemokine measurements) as well as paired Student's t-test (migration experiments).
Results: Measurements of chemokine levels revealed an increase in three of the four known major B cell
chemoattractants CXCL13, CCL19 and CXCL12 in LNB CSF. The CXCL13 CSF:serum ratio, as a measure of
the chemotactic gradient, was substantially higher than that of CCL19 and CXCL12. Moreover, the chemotactic
activity of LNB CSF was reduced up to 56% after preincubation with a neutralizing CXCL13 antibody, while
combined preincubation with antibodies against CXCL13, CCL19, and CXCL12 did not lead to further reduction.
Since treatment with pertussis toxin, heating to 60°C, and removal of proteins >3 kDa abrogated the chemotactic
activity, further not yet identified chemokines seem to be involved in B cell recruitment to LNB CSF.
Conclusion: Combined, our study suggests a key role of CXCL13 in B cell migration to sites of infection as
shown here for the CSF of LNB patients.
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Background
The field of function of CXCL13 has been constantly
growing since its discovery in 1998 [1]. Initially, the essen-
tial role of CXCL13 was seen in the establishment and
maintenance of lymphoid tissue microarchitecture [2].
Accordingly, CXCL13 deficient mice fail to develop lymph
nodes [3], and B-cell homing to lymph node follicles
requires CXCL13 and its exclusive receptor CXCR5 [4].
Some years later, evidence for a role in the formation of
ectopic lymphoid tissue in chronic inflammation such as
multiple sclerosis or rheumatoid arthritis was also found
[5,6]. Finally, the detection of CXCL13 expression in Heli-
cobacter pylori gastritis [7], pulmonary tuberculosis [8] or
Bartonella henselae infection [9] suggested a role of this
chemokine in chronic bacterial infections as well. Its
influence on leucocyte migration to the site of infection,
however, has not been evaluated so far.
Recently, we and others observed a strong up-regulation
of CXCL13 expression in an acute bacterial infection, in
Lyme neuroborreliosis (LNB) [10,11]. In LNB, the spiro-
chete Borrelia burgdorferi (B.b.) invades the cerebrospinal
fluid (CSF) [12]. The host immune system reacts to the
invading spirochetes with a local inflammation, leading
to an intrathecal accumulation of leucocytes. A hallmark
of this CSF-pleocytosis in LNB is the accumulation of acti-
vated B cells and plasma cells. The percentage of B cells in
the CSF of LNB patients reaches up to 80%, clearly exceed-
ing other CNS infections [13]. B cells show a substantial
migration only to very few chemokines, namely, CCL19,
CCL21, CXCL12, and CXCL13 [14].
In previous studies, we measured high concentrations of
CXCL13 in the CSF of patients with LNB, even before the
intrathecal production of B.b.-specific antibodies has
started [10,15]. Cell culture experiments have shown, that
PBMC produce CXCL13 in response to an incubation
with B.b. through the interaction of the TLR2 receptor of
the innate immune system with spirochete outer surface
proteins [16]. This in vitro study is further supported by
findings in the rhesus monkey model of LNB, where the
CXCL13 expression at the spinal nerve roots correlated
with the spirochete load and resident immune cells have
been identified as source of this chemokine [11,17]. Based
on these data, we speculated that in vivo, the high intrath-
ecal concentration of CXCL13 in LNB patients directs the
B cells to the CSF, leading to the observed B cell enriched
CSF pleocytosis [12].
To further assess the role of CXCL13 for the B cell rich
infiltrate in the CSF of LNB patients, we (1) examined the
chemotactic activity of CSF samples from patients with
LNB on human B cells, compared with that of patients
with a non-inflammatory CNS diseases (NIND), and neu-
rosyphilis (NS) as another spirochete CNS disease in a
chemotaxis assay, (2) determined the concentrations of
CXCL13 and other B cell attracting chemokines in CSF/
serum pairs of the three patient groups, and (3) tried to
elucidate the contribution of these chemokines to the
chemotactic activity of LNB by using specific neutralizing
antibodies.
Methods
B-cell isolation and stimulation
Human peripheral blood mononuclear cells were
extracted from venous blood samples from a healthy male
donor using ficoll gradient centrifugation. Subsequent
untouched B cells were isolated by Midi Macs System®
(Miltenyi Biotec, Bergisch-Gladbach, Germany). The
purity of the (CD19+) B cells, examined repetitively before
and during the experiments by a FACS analysis, was
always higher than 98.4%. More than 95% of isolated
cells were shown by the Trypan blue exclusion test to be
viable. In order to stimulate the B cells to increase their
migratory ability, they were incubated for 16 hours at
37°C and 5% CO2 in RPMI1640 medium supplemented
with 10%FCS, 100 units penicillin and 100 μg streptomy-
cin/ml, 20 ng/ml IL4 and 1 μg/ml CD40L according to
[14]. Thereafter, the cells were pelleted again and diluted
to a working concentration of 2.6 × 10^6 cells/ml for the
migration assays and 2.1 × 10^6 cells/ml for the inhibi-
tion assays.
CSF/blood samples
Blood was drawn and lumbar puncture was performed for
diagnostic purposes after the patient's informed consent
was obtained. All samples were frozen at -30°C. Paired
CSF and blood samples were obtained from the following
groups:
(i) 14 patients (9 males) with non-inflammatory CNS dis-
ease (NIND). The mean cell count was 1.8 [0.3-4.7] cells/
μl, and the mean CSF/serum albumin ratio was 8.7 [3.3-
31.0]. The mean age was 64.7 [48-74] years. Three of these
patients suffered from chronic pain, two others had an
epileptic seizure, and the further patients were diagnosed
amyotrophic lateral sclerosis, vascular compression of the
brain stem, Parkinson's disease, transverse myelitis, Guil-
lain-Barré syndrome, multiple sclerosis, herniated verte-
bral disc, somatoform disorder or progressive ataxia.
(ii) 18 patients (11 males) with acute (duration of symp-
toms < 6 months) Lyme neuroborreliosis (LNB) before
initiation of therapy. The mean cell count was 146 [1-600]
cells/μl (for details, please refer to table 1), the mean CSF/
serum albumin ratio was 26.0 [3.9-43.9]. The mean age
was 57.8 [15-72] years. The diagnosis of LNB was based
on the following criteria: 1) typical clinical picture (e.g.
meningoradiculitis, cranial neuritis or meningitis) 2) lym-
phocytic CSF pleocytosis, and 3) increased intrathecalJournal of Neuroinflammation 2009, 6:42 http://www.jneuroinflammation.com/content/6/1/42
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B.b.-specific antibody production. Detailed data concern-
ing basic CSF findings as well as the B.b.-specific antibody
index and the percentage of plasma cells are given in
table 1.
(iii) 14 patients (13 males) with neurosyphilis (NS). The
mean cell count was 17.4 [5-45] cells/μl and the mean
CSF/serum albumin ratio was 5.9 [3.2-12.5]. The mean
age was 31.8 [19-48] years. The diagnosis was based on
serological proof of a syphilitic infection (positive
Treponema particle agglutination and fluorescent trepone-
mal antibody absorbed tests) and an elevated CSF white
blood cell count according to the criteria described by
Marra et al. [18]. All patients with syphilis were in the sec-
ond stage of disease (secondary syphilis) and negative for
the human immunodeficiency virus (HIV).
Migration assay
The migration assay was performed in a disposable 96-
well system (ChemoTx, Neuroprobe) with polycarbonate
membrane filters (5 μm pore). 30 μl of the CSF samples
were added to the lower chamber and 50 μl B cell solution
was added onto the membrane. The chamber was incu-
bated for 1 h at 37° in humidified air with 5% CO2. After
incubation, the migrated cells in the lower chamber were
counted in a Fuchs-Rosenthal-chamber.
Table 1: Clinical data and basic CSF parameters of the LNB patients
Pat. Nr. Gender 
f/m
Age 
[y]
Clinical syndrome Cell count 
[/ l]
Plasma cells
[%]
Albumin quotient1 Antibody index2
1 f6 9 B S 5 3 1 5 4 3 . 9 1 . 7
2 m 15 CNP, M 600 0 5.4 4
3 f7 0 B S 9 0 0 4 . 8 3 n . d . +
4 m 62 BS, CNP 246 16 39.7 7.3
5 f 69 BS 109 5 15.8 13.3
6 f 61 BS 217 1 37.9 40.7
7 m 66 BS, CNP 16 0 8.9 <1.5#
8 m6 7 B S ,  M 5 2 2 0 1 0 . 3 3 4
9 m 61 BS 1* 8 30.3 10.9
10 m 72 CNP 166 3 21.6 62.7
11 m5 9 B S 1 0 0 0 2 3 . 4 2 . 8
12 m 38 M 117 11 26 168
13 m 55 BS, CNP 368 n.d. 19.1 38.6
14 m 50 CNP 12 0 4.5 7.7
15 f4 6 B S 1 4 0 3 . 9 1 . 8
16 m 59 BS 30 0 13.2 2.5
17 f 59 BS 255 5 33.2 17.8
18 f 62 CNP, M 180 1 10.5 4.3
BS: Bannwarth's syndrome (meningopolyradiculitis), CNP: Cerebral nerve palsy (Cranial neuritis), M: Meningitis. 1CSF/serum albumin quotient, 
2B.b.-specific antibody index. * = cell count at follow up lumbar puncture (8 days later) showed 70 leucocytes/μl and an increasing antibody index 
(27.5). + antibody index initially not done, but on repeated lumbar puncture 13 days later, the CSF showed an B.b.-specific antibody index of 9.34 
(and cell count of 102/μl). # antibody index at follow up 4 days later 2.1, and 12 days later 4.8 (and cell count of 13, and 17, respectively).Journal of Neuroinflammation 2009, 6:42 http://www.jneuroinflammation.com/content/6/1/42
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For better comparison of the results from different exper-
iments, a migration index was calculated. We used
medium as negative control value and 500 ng/ml
rhCXCL13 (R&D Systems, Minneapolis, MN, USA) as a
positive control.
The results are presented in per cent. A MI of 100% impli-
cates, that the sample had the same chemotactic effect as
500 ng rhCXCL13.
FACS analysis
Anti-human monoclonal antibodies against CD19 (PC5,
J3-119, IgG1) and CD27 (PE, 1A4, IgG1), obtained by
Immunotech (Marseille Cedex, France) were used. For
flow cytometry 50 μl cell suspension (2 × 106/ml) of iso-
lated B cells and either B cells, which did migrate to
rhCXCL13 or LNB CSF, and those that have not migrated
were incubated with 5 μl of CD19 and 10 μl of CD27 each
for 15 minutes at room temperature in the dark. 1 ml Peli-
Lyse lysing reagent (Hiss Diagnostics GmbH, Freiburg,
Germany) was added to each of the tubes and incubated
for another 10 minutes in the dark at room temperature.
The cells were washed and resuspended in 200 μl PBS
(Merck KGaA, Darmstadt, Germany) and afterwards
immediately analysed.
Analysis was performed on a FACS Canto II flow cytome-
ter (Becton Dickinson, San Jose, USA) using FACSDiva
software. 10,000 events were acquired. Data were dis-
played as two colour plots (CD19/CD27). The data of
migrated B cells were compared with those of non
migrated B cells.
ELISA
From the CSF/serum samples used for the migration
assays, sufficient volume for the quantitative measure-
ment of the chemokines CXCL12, CCL19 and CCL21 was
available from 12 NIND (mean cell count 1.89/μl, mean
total CSF protein 553 mg/l, mean age 65.2 years, and 58%
male), 14 NB (mean cell count 375.6/μl, CSF protein
1,186 mg/l, mean age 56.4 years, and 64% male) and all
NS patients. CXCL13 levels in CSF and serum samples
were measured in all samples used in the migration
assays. A part of the samples have already been analysed
for CXCL13 before [10,16]. The measurements were done
by ELISA (R&D) according to the recommendations of the
manufacturer.
Inhibition assay
To investigate the chemotactic impact of CXCL13,
CXCL12 and CCL19 on the human B cells, the respective
chemokines in the CSF samples from LNB patients were
blocked with neutralizing antibodies. For the isolated
blockade of CXCL13 activity, 10 μg/ml of the neutralizing
polyclonal CXCL13 antibody or an isotype control anti-
body (10 μg/ml) (all R&D) was used. For triple inhibition
assays, we added additional 10 μg/ml polyclonal CCL19
and 50 μg/ml polyclonal CXCL12 antibody or analogous
amounts of isotype control antibodies. In pre-tests, we
could show that the CXCL13 and CCL19 antibodies
inhibit >99% of the chemotactic effect of 50 ng/ml
rhCXCL13 and rhCCL19, respectively. In contrast, though
testing several available neutralizing antibodies in differ-
ent concentrations, the blockade of CXCL12 activity only
reached 42%. Cross reactivity between all applied anti-
bodies was tested and not observed. All samples were pre-
incubated on a shaker with the respective antibody for 30
min at RT. As negative control, we used a mixture from 12
CSF samples from NIND patients as they would represent
the baseline of migratory activity in vivo, 500 ng/ml
rhCXCL13 served as positive control. To perform the
assay, sufficient CSF volume from 12 patients was availa-
ble, but only 9 samples were tested as their MI was higher
than all NIND samples. In addition, 3 LNB CSF samples
were either heated at 60°C for 10 minutes to denature
protein structures, filtrated for 90 min at 14 g using a
membrane with a 3 kDa Nominal Molecular Weight Limit
(Millipore), or the B cells were preincubated for 90 min
with 5 μg/ml PTx. All experiments were performed in
duplicate.
Statistics
In order to assess statistical significant differences of the
chemotactic activity of CSF samples obtained from
patients with NIND, LNB, or NS on isolated B cells we
used one way analysis of variance (ANOVA) and Bonfer-
roni adjustment. This statistical test was also used to
measure the significant differences between the chemok-
ine concentrations of these groups in the ELISA assays.
The paired t-test was used to measure the differences in
the migration behaviour of B cells between antibody- and
isobody-control groups in the inhibition assays. The data
were expressed as mean ± SD.
Results
Chemotactic activity of CXCL13 and CSF from LNB 
patients on B cells
First, we determined the chemotactic impact of recom-
binant human (rh)CXCL13 on human B cells in a well
established chemotaxis assay, the modified boyden cham-
ber [19,20]. rhCXCL13 had a dose-dependent chemotac-
tic activity by increasing the amount of migrating B cells
between 1.5-fold (at 5 ng/ml) and 7.4-fold (at 500 ng/ml)
in comparison to the medium control (data not shown).
The proportion of mature, CD27+ B cells was 73.9% in
the migrated cells, while only 25.5% of the non-migrated
cells were expressing this activation marker (Fig. 1d).
Next, we analysed the migratory activity of CSF samples
from different patient groups (NIND, LNB, and NS) on B
cells. The migratory index (MI, for details please refer to
MI sample result negative control positive control neg =− − (( ) /(      a ative control  ))×100Journal of Neuroinflammation 2009, 6:42 http://www.jneuroinflammation.com/content/6/1/42
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the Methods section), was clearly higher for the LNB
group (MI = 116) than for both other patient groups (32.1
for NIND and 16.8 for NS, p < 0.001) (Fig. 1a). Similar to
rhCXCL13, 65.5% of the B cells that have migrated
towards the CSF of LNB patients were expressing CD27, in
contrast to 26% of the non-migrating cells (Fig. 1b-d).
Together, these findings indicate, that predominantly
mature, activated B cells are attracted by both, rhCXCL13
(in concentrations as found in the CSF of LNB patients)
and the CSF of LNB patients.
Concentration of B cell-attracting chemokines in CSF/
serum sample-pairs
To identify the immune factors responsible for the
increased chemotactic activity of CSF samples from LNB
patients, we measured the concentration of the four major
B cell attracting chemokines CXCL13, CCL19, CXCL12
and CCL21 in CSF samples from all three patient groups
(LNB, NIND and NS). The concentration of CXCL13 was
significantly increased in the CSF of LNB patients (mean
= 7,864 pg/ml, range 209-26,769) compared to NIND (25
pg/ml, 0-188) and NS patients (426 pg/ml, 0-750, Fig.
2a). A significant higher level in LNB patients than in both
other patient groups was also found for CCL19 (400 pg/
ml, 72-959 vs. 52 pg/ml, 21-107 in NIND and 104 pg/ml,
42-176 in NS patients, Fig. 2d). For CXCL12, the differ-
ence was significant between LNB (1,797 pg/ml, 404-
3,963) and NIND (564 pg/ml, 0-938), but not NS (1,239
pg/ml, 759-1,818, Fig. 2g). For CCL21 (1 pg/ml, 0-13 in
LNB vs. 17 pg/ml, 0-140 in NIND and 12 pg/ml, 0-75 in
NS) no significant difference between the patient groups
was observed. These findings argue for a role of CXCL13,
CCL19, and CXCL12, but not CCL21 for B cell recruit-
ment in LNB.
As a chemotactic gradient is a major determinant of chem-
otactic activity, the concentration of each chemokine was
also measured in the corresponding serum samples (Fig.
2b, e, and 2h) and the CSF-to-serum ratio (CSR) was cal-
culated. While an increased CSR in LNB was detected for
CCL19 (CSR = 5, Fig. 2f) and a marginal difference was
found for CXCL12 (CSR = 1.1, Fig. 2i), the most impres-
sive gradient, 28.6 fold higher than that of CCL19, was
found for CXCL13 (CSR = 143, Fig. 2c). In a next step, the
CSR of the three chemokines was plotted with the MI of
the respective CSF samples. As visualized in Fig. 3, the CSR
of both, CXCL13 and CCL19, but not CXCL12 was found
to be associated with an elevated MI. Combining the high
chemotactic gradient and its association with the MI,
CXCL13 appears to be the major candidate for a func-
tional role in B cell recruitment to the CSF in LNB.
Blocking the migration with neutralizing chemokine 
antibodies
The functional role of the B cell attracting chemokines was
further analysed using neutralizing antibodies. CSF sam-
ples of LNB patients were preincubated with either a neu-
tralizing CXCL13-antibody alone or all three (CCL19,
CXCL12 and CXCL13) antibodies together. Compared
with the isotype controls, blocking the CXCL13 activity
alone reduces the percentage of migrated cells up to 56%
(mean 36.2%, p = 0.005) (Fig. 4a). In more than 50% of
Migration of B cells to CSF samples Figure 1
Migration of B cells to CSF samples. (A) migration index of CD19+ B cells to CSF samples from different patient groups, 
horizontal bars represent the mean value, *: p < 0.001. (B) and (C) exemplary result of a FACS analysis of (B) migrated or (C) 
not-migrated CD19+CD27+ B cells towards the CSF sample of a LNB patient. (D) percentage of migrated vs. not-migrated 
CD27+CD19+ B cells, using either CSF-samples of patients with LNB (n = 3) or 500 ng/ml rhCXCL13 (mean of two independ-
ent experiments, done in duplicate) as chemotactic agents.
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the samples, the addition of CCL19 and CXCL12 did not
further substantially decrease the migratory activity. How-
ever, in patient Nr. 3, neutralizing CXCL13 alone had
hardly any effect, while all three antibodies together
reduced the migration by nearly 50%. Therefore, the
CCL19- and CXCL12- antibodies were also separately
tested in this sample, and the neutralizing capacity of the
CCL19-antibody was more than 2-fold higher than that of
the CXCL12 antibody (Fig. 4b). Taken together, the inhi-
bition assays show that CXCL13 seems to play the domi-
nant functional role for B cell migration to LNB CSF, but
both CCL19 and CXCL12 might contribute in selected
samples.
Additional, yet unidentified chemotactic factors may also 
be involved
Although our results suggest that CXCL13 is a key deter-
minant of chemotactic activity for B cells in LNB, addi-
tional factors appear to be involved as the inhibition has
not been complete. To get a first insight into further
Concentration of Chemokines in CSF samples Figure 2
Concentration of Chemokines in CSF samples. Concentration of the respective chemokines in either CSF- (A, D, and 
G) or serum-samples (B, E, and H) of the different patient groups, and accordingly the calculated CSF-to-serum ratio (C, F, and 
I), horizontal bars represent the mean value, *: p < 0.001, $: p = 0.003, and #: p = 0.021 vs. LNB, and +: p < 0.001, and § p = 
0.013 vs. NS
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Correlation of the CSF-to-serum ratio of chemokines with the migration index Figure 3
Correlation of the CSF-to-serum ratio of chemokines with the migration index. Correlation of the CSR of the dif-
ferent chemokines with the MI of the respective CSF sample as measured in the migration assay. A cut-off for the MI was set at 
80, as all CSF samples from NIND patients (and accordingly no inflammatory cell infiltrate in the CSF) had a MI below this value 
(horizontal dotted line). The vertical dotted line separates the samples with a "negative" CSR (<1) from those with a "positive" 
CSR (>1). A high proportion of CSF samples in the upper right or lower left quadrant indicate a positive association.
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immune factors involved, we either filtered the CSF sam-
ples to eliminate components with more than 3 kDa,
denaturized proteins by heating the samples at 60°C or
preincubated the B-cells with Bordetella pertussis toxin
(PTx) to exclude signalling via Gi-proteins (as used by the
chemokines [21]). While PTx treatment and heating
reduced the migratory activity by approximately 80%, the
filtration of components larger than 3 kDa completely
eliminated the chemotactic effect. This pattern was simi-
lar, if rhCXCL13 was used as chemotactic agent (Fig. 5).
Taken together, these yet unidentified chemotactic factors
have to be larger than 3 kDa, are predominantly heat sen-
sitive and signal via Gi-proteins.
Discussion
The mechanisms underlying the B cell rich CSF pleocyto-
sis in LNB are still undefined. Here we demonstrate that
CSF of LNB patients is chemotactic to peripheral blood
human B cells, and that CXCL13 is a major regulator of B
cell recruitment in acute LNB.
The cells that migrated towards the CSF of LNB patients in
our in vitro setting were predominantly CD27+ B cells. The
surface marker CD27+ on B cells indicates, that these cells
are activated and can produce 5- to 100-fold more immu-
noglobulins than CD27- cells [22]. Earlier studies on the
immune response during the course of B.b. meningo-
radiculitis revealed, that large numbers of B cells in the
CSF and a prominent intrathecal production of antigens
are characteristic for LNB [13], suggesting that these B-
cells are from the (CD27+) mature type. The exact rate of
CD27+ cells in the CSF in LNB, however, has not been
determined so far. Results from patients with other neu-
roinflammatory disorders like multiple sclerosis, viral
infections, or neurosyphilis showed that 85% of the total
B cell population in the CSF are CD27+, in contrast to
31% in the peripheral blood [23]. Taken these studies
together, CD27+ B cells appear to be the main migrating B
cell population in neuroinflammation, both in vivo and in
our  in vitro experimental setup. Therefore, our in vitro
model seems to be a suitable tool to search for the respon-
sible chemotactic agent for B cell immigration in LNB.
This chemotactic agent should fulfil four criteria: a) it has
to attract B cells, b) it has to be elevated in the CSF of LNB
patients and there must be a gradient over the blood-CSF
barrier, c) there should be an association between the gra-
dient and the intensity of B-cell-migration, and d) its neu-
tralization should abrogate the observed B cell migration
to LNB CSF. The four known major B cell attracting chem-
okines are CCL19, CCL21, CXCL12, and CXCL13, as
shown by Brandes et al. [14]. From recent studies, it is
known that CXCL13 is elevated in the CSF, but not the
blood of LNB patients [10,16]. In the current study, we
further showed that rhCXCL13, when used in concentra-
tions as found in LNB CSF samples, is chemotactic to B
cells. Data concerning the concentration of other B-cell
attracting chemokines in LNB CSF are rarely found in the
literature. Only CXCL12 was explicitly measured in a
small collective of 6 LNB patients with a mean of 24.1 ng/
ml in the CSF of LNB patients and 5.5 ng/ml in NIND
patients [24,25]. Elevated levels of CCL19 in the CSF of
patients with various infectious diseases (including LNB
patients) were determined by two study groups [26,27]
with a mean value between 173 - 250 pg/ml compared to
26 - 62 pg/ml in NIND patients. CCL21 in contrast was
not found at measurable concentrations in any of these
studies. Exact data for LNB patients or serum concentra-
tions to calculate the gradient of CCL19 or CCL21 were
not available. Therefore, we measured the concentrations
of CCL19, CCL21, CXCL12 and CXCL13 in CSF/serum
pairs of patients with LNB. The most prominent results
were found as expected for CXCL13 [10,16] with a more
than 300 fold difference in the CSF between LNB and
NIND patients and a mean CSR of approximately 150.
All of the LNB patients had not been treated with antibi-
otics before the lumbar puncture. One of the NS patients
Inhibition of migration with neutralizing antibodies Figure 4
Inhibition of migration with neutralizing antibodies. 
(A) Inhibition of the chemotactic effect of CSF samples from 
9 LNB patients (same enumeration as in table 1) with the 
indicated antibody (in % compared with the respective iso-
type control). (B) All antibodies were used separately in 
patient Nr. 3, where the CXCL13 antibody alone had no rel-
evant effect.
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received an antibiotic therapy for two weeks before CSF
sampling and showed the lowest CXCL13 CSF value of all
NS patients. This observation fits perfectly to recent stud-
ies demonstrating that (I) viable spirochetes are needed
for the production of CXCL13 in monocytic cells [16] and
(II) CSF CXCL13 concentrations rapidly decreases under
antibiotic therapy in LNB patients [10].
The difference between the patient groups is less impres-
sive for CCL19 but still compatible with a functional
chemotactic role: The mean CSF concentration is 8 fold
higher than in NIND patients and the mean CSR equals 5.
The results obtained for CXCL12 are lower than those
from Pashenkov et al. [24], but the high constitutive
expression of CXCL12 in the CNS and the lack of an ele-
vated CSR, arguing against a functional role for B cell
immigration, was confirmed in our study. The concentra-
tion of CCL21 in the CSF, as expected from previous stud-
ies, is hardly measurable in any patient group and a
functional role therefore very unlikely. In view of these
results, CXCL13, but also CCL19 and less likely CXCL12
were identified as putative chemotactic agents in LNB.
This was further underlined by the association analysis.
High CXCL13 and CCL19, but not CXCL12 concentra-
tions in LNB CSF were associated with a high MI. Finally,
the neutralization experiments underlined the key role of
CXCL13, since preincubation with anti-CXCL13 antibod-
ies significantly reduced the migration activity of B cells.
Therefore CXCL13 fulfils all criteria as stated above.
CCL19 instead, which signals via the CCR7 receptor,
appears to play a functional role for B-cells only in single
cases (as seen in patient Nr. 3, Fig. 4). However, this
chemokine could be important for the immigration of T-
lymphocytes instead, as suggested in the literature. Acti-
vated T-lymphocytes strongly upregulate CCR7 and effi-
ciently migrate to CCL19 [28], and T-lymphocytes found
in the CSF of patients with (not further specified) inflam-
matory CNS-diseases are CCR7 positive [27]. As CCL19 is
much stronger chemotactic for T than for B cells, its role
in LNB could be the attraction of T cells, but this would
have to be determined in further studies.
For the association analysis as shown in Figure 3, the cut-
off for an increased migration index was set at 80, as the
CSF of all NIND-patients had a migration below this
value. As seen in Figure 3A and 3B and also in Figure 1A,
there are four CSF samples from LNB patient with a migra-
tion index below 80. The one of them with the highest MI
also has a high CSR for CXCL13 and resembles in its basic
CSF findings the other LNB patients (cell count 368/μl,
albumin CSF/serum quotient 19.1). The three others,
however, appear to be a distinct group. They are combin-
ing a low CSR for both CXCL13 (7-18.5) and CCL19 (0.7-
1.7) with a low migration index. Compared to the remain-
ing LNB patients, they also have a lower cell count (19 ±
10 vs. 146 ± 152 cells/μl, p < 0.01), albumin CSF/serum
quotient (7.2 ± 5.2 vs. 19.6 ± 13, p = 0.02), and in none
of them, plasma cells are found in the CSF (in contrast to
a mean of 5% in the other LNB patients, p < 0.01.).
Although these data should be interpreted with caution,
given the small sample size of this subgroup, the observa-
tion that in all three patients low-grade inflammatory CSF
changes were paralleled by very low CSRs for CXCL13 and
CCL19 (as compared to other LNB patients) further
underlines the functional role of both chemokines. It also
has to be mentioned that the less pronounced CSF altera-
tions in this LNB subgroup are not reflected by less (or dif-
ferent) clinical symptoms or by clear differences in age or
gender. However, we are not aware of the duration
between the onset of symptoms and lumbar puncture.
Both the quantity and quality of CSF abnormalities (e.g.
CSF pleocytosis and CSF chemokine levels) may change
over time after infection, which may be an interesting
topic to be addressed in future studies.
As the inhibition of CXCL13, CCL19 and CXCL12 does
not completely abrogate the chemotactic activity of LNB
CSF samples, additional factors have to be involved. In a
study by Dubois et al., the supernatant of cultured den-
dritic cells was found to be chemotactic for B cells [29]. As
the supernatant was insensitive to PTx treatment, the
Inhibition of migration with PTx, heating, or filtration of sub- stances >3 kDa Figure 5
Inhibition of migration with PTx, heating, or filtra-
tion of substances >3 kDa. CSF samples of LNB patients 
(n = 3, black bars) or 500 ng/ml rhCXCL13 (mean of two 
independent experiments, done in duplicates, gray bars) 
were used as chemotactic agent. Either, the B-cells were pre-
incubated with PTx, or the chemotactic agent was either fil-
trated to eliminate substances larger than 3 kDa or heated at 
60°C prior to the migration assay. The reduction of migra-
tion was compared to the untreated B cells, or the untreated 
chemotactic agents, respectively.
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authors stated that the relevant factors have to be different
from classical chemoattractants. In our study, however,
the chemotactic activity of both, rhCXCL13 and LNB CSF
was reduced by around 80% by interfering with the PTx
pathway, and also heat treatment. In addition, the chem-
otactic activity of LNB CSF samples and rhCXCL13 was
completely blocked by eliminating all substances larger
than 3 kDa. Chemokines weigh between 6 and 14 kDa
[30], signal predominantly via the PTx-sensitive pathway
[31], and are as proteins heat sensitive. This indicates that,
besides CXCL13, another "similar" chemokine could be
responsible for the remaining chemotactic activity after
blockade of CXCL13. Another possible candidate could
be the complement, as the size of complement factors
ranges from 24 to 410 kDa, they are heat sensitive and - as
shown for C5a - signal via PTx-sensitive G proteins [32].
In addition, it has been demonstrated, that B.b. can
induce the production of complement in vitro and in vivo
[33,34] and that B cells respond chemotactic to C5a [35].
However, there are even more substances to be consid-
ered: components of the Borrelia themselves could also
contribute to the chemotaxis. In a study by Benach et al.,
large proteins of the borrelial membrane like the Outer
surface protein A or flagellin had a chemotactic effect on
leucocytes [36]. Taken together, further studies are war-
ranted to identify all factors involved in B cell attraction.
Conclusions
In summary, CXCL13 plays a key role for the immigration
of B cells into the CSF in LNB. Therefore - apart from its
unquestioned role in dictating homing and motility of
lymphocytes in lymphoid tissues [37] - this potent B cell
attracting chemokine appears to be also important for
attracting B cells to sites of acute bacterial infection.
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